logo

Harnessing the innate and adaptive immune system with targeted neoantigen based cancer vaccines

Location: Spain

Source: EU Funding & Tenders Portal

Project
Ended

Immunotherapy for cancer has recently shown great clinical potential. However, only small percentages of patients do benefit from these therapies. The dual objective of the proposal is to understand and harness the immune system in vivo to develop truly personalized (individualized) anti-cancer treatments and to develop powerful bioconjugation technologies to generate new and better biotherapeutic

Project Information FAQ

Project Information

3 Q
The project “Harnessing the innate and adaptive immune system with targeted neoantigen based cancer vaccines” is an infrastructure initiative, located in Spain. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Immunotherapy for cancer has recently shown great clinical potential. However, only small percentages of patients do benefit from these therapies. The dual objective of the proposal is to understand and harness the immune system in vivo to develop truly personalized (individualized) anti-cancer treatments and to develop powerful bioconjugation technologies to generate new and better biotherapeutics. The project objectives will be achieved through the combination of ProteoDesign’s site-specific bioconjugation technology, with recent advances in the field of immuno-oncology, particularly the importance of tumor specific mutations (neoantigens), as drivers of anti-tumor immunity. The therapeutic candidates that will be obtained as a result of the project are personalized and have the potential to treat cancer at the individual level. These therapies are based on the mutational landscape of any given tumor, and so they could be applied to multiple cancer indications. The proposal will face specific challenges regarding the development of complex personalized bio therapeutics. The project will be carried out through the collaboration of Dr. Vanhooren and Barcelona based biotech ProteoDesign. Dr. Vanhooren has extensive know-how and experience in the pre-clinical development of biologic-based drugs, and ProteoDesign has a proprietary technology for the discovery and development of new therapeutic bioconjugates. Through the present proposal bidirectional knowledge transfer will take place between the fellow and the host, thus enhancing know-how and skills on both sides. Dr. Vanhooren will be focused on leading the project, setting and adapting objectives, designing experiments, supervising the team and analyzing results. During the project and through a specific plan, ProteoDesign will provide Dr. Vanhooren experience and knowledge in key areas of biotechnology and pharma industries, as well as senior management, to allow her to grow into high responsibility positions.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data